Orchard Therapeutics plc (ORTX) |
|
0.57 -0.014 (-2.43%)
|
07-02 18:44 |
|
Open: |
0.57 |
Pre. Close: |
0.5842 |
|
High:
|
0.62 |
Low:
|
0.56 |
|
Volume:
|
1,417,680 |
Market Cap:
|
72(M) |
|
|
|
|
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.62 - 0.62 |
0.62 - 0.63 |
|
Low:
|
0.55 - 0.56 |
0.56 - 0.56 |
|
Close:
|
0.56 - 0.57 |
0.57 - 0.58 |
|
Technical analysis |
as of: 2022-07-01 4:24:13 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.74 One year: 0.87 |
| Support: |
Support1: 0.52 Support2: 0.44 |
| Resistance: |
Resistance1: 0.63 Resistance2: 0.74 |
| Pivot: |
0.56  |
| Moving Average: |
MA(5): 0.57 MA(20): 0.54
MA(100): 0.66  MA(250): 1.48 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 62.4 %D(3): 60.6 |
| RSI: |
RSI(14): 53.9 |
| 52-week: |
High: 4 Low: 0.4 |
| Average Vol(K): |
3-Month: 790 (K) 10-Days: 1,478 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ORTX ] has closed below upper band by 46.8%. Bollinger Bands are 43% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Sat, 18 Jun 2022
Orchard Therapeutics (NASDAQ:ORTX) & Miromatrix Medical (NASDAQ:MIRO) Head-To-Head Comparison - Defense World
Thu, 26 May 2022
$3.86 Million in Sales Expected for Orchard Therapeutics plc (NASDAQ:ORTX) This Quarter - Defense World
Thu, 12 May 2022
Orchard Therapeutics PLC (ORTX) CEO Bobby Gaspar on Q1 2022 Results - Earnings Call Transcript - Seeking Alpha
Tue, 10 May 2022
Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond - Yahoo Finance
Tue, 29 Mar 2022
Pre-Market Earnings Report for March 30, 2022 : PAYX, BNTX, FIVE, AER, MSM, UNF, AXLA, TCRT, ORTX, CAAS, PTE - Nasdaq
Mon, 21 Mar 2022
What Kind Of Shareholders Hold The Majority In Orchard Therapeutics plc's (NASDAQ:ORTX) Shares? - Simply Wall St
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
126 (M) |
|
% Held by Insiders
|
7.152e+007 (%) |
|
% Held by Institutions
|
0.4 (%) |
|
Shares Short
|
1,540 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.3811e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-8 |
|
Return on Assets (ttm)
|
384 |
|
Return on Equity (ttm)
|
-29.2 |
|
Qtrly Rev. Growth
|
1.68e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-64.74 |
|
EBITDA (p.s.)
|
-7.43739e+007 |
|
Qtrly Earnings Growth
|
-1.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-125 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
0.33 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
777940 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
